IMS: in 2020, the market of biological similar drugs will reach 110 billion US dollars!

Source: bioprospecting 2016-3-31 according to the data of IMS, a world-renowned medical information provider: by 2020, only in Europe and the United States, the market of biological similar drugs will reach 110 billion US dollars With the expiration of patent drugs, biological similar drugs will occupy 20% of the market in the next five years The report points out that at present, there are nearly 50 kinds of biological similar drugs in the research and development, and the competitive products are mainly several global heavyweight drugs, with Humira, Enbrel, REMICADE and rituxan as the main IMS (see the table below) Point out: of course, the price of the first bionic product is not much cheaper than that of the original research drug, but there is still a certain profit range for the cost of splitting up the drug The extent of its profitability depends on the regulation of policies, especially in the EU, where the reimbursement policies for many bio similar drugs are very limited The proportion of reimbursement for bio similar drugs in each country is different (see the figure below): over time, the prices of brand bio preparations and bio generic drugs will increase (see the table below): as the patent expires, the bio generic drugs of adalimumab, an antibody drug for rheumatoid arthritis, will face fierce competition In addition, there are the following similar drugs for biological products under competitive pressure The report points out that encouraging a "viable competitive market" between biosimilars and original research drugs is an important way to open the public's savings and improve the accessibility of drugs The IMS report also pointed out that the health care system should effectively utilize and give full play to the competitive initiative of bio similar drugs, and encourage pharmaceutical companies to participate in the core process of doctors' decision-making for a long time.